Sequential azacitidine and carboplatin can prime high-grade serous ovarian cancer to respond to checkpoint inhibitor immunotherapy.
Ontology highlight
ABSTRACT: Sequential azacitidine and carboplatin can prime high-grade serous ovarian cancer to respond to checkpoint inhibitor immunotherapy.
PROVIDER: PRJNA717226 | ENA |
REPOSITORIES: ENA
ACCESS DATA